Introduction
Melanoma remains a major world health problem (1, 2) , though recent advances in targeted therapy against oncogenic BRAF for melanoma have shown some promising results (3) . Somatic mutations in the BRAF oncogene occur in over half of melanomas, with the vast majority of these harboring an activating point mutation (V600E) (3) . This oncogenic mutation leads to constitutive activation of the MAPK signaling pathway and increased oncogenic potential through a variety of mechanisms including reduced apoptosis, increased invasiveness, and increased metastatic behavior (4) . Recent in vitro data also suggest that BRAF V600E could also contribute to immune escape (5) .
Targeted therapy against oncogenic BRAF for metastatic melanoma results in objective responses in the majority of patients whose tumors harbor BRAF V600E (6) .
Despite this, resistance to therapy remains a significant issue, with a median duration of response between 6 and 7 months (6) . There is a great deal of ongoing research to determine mechanisms of resistance and strategies to overcome resistance (7) (8) (9) .
Multiple distinct mechanisms of resistance have already been identified in recent months (10) (11) (12) (13) .
Combination of BRAF-targeted therapy with other signal transduction inhibitors has been proposed based on evidence that other pathways become activated upon emergence of resistance (14) and such clinical approaches are already underway. metastatic melanoma receiving BRAF-targeted therapy and CD8+ T cell infiltrate correlated with response to therapy (15, 16) .
We sought to test the hypothesis that BRAF-targeted therapy is associated with improved melanoma antigen expression and an enhanced immune response in patients with metastatic melanoma. We also assayed immune-modulatory cytokines and markers of T cell cytotoxicity as well as T cell exhaustion markers and the immunosuppressive ligand PDL1 to gain insight into potential means to modulate the immune response to BRAF inhibition.
Materials and Methods

Patient Samples
Patients with metastatic melanoma containing BRAF Table S1 ) and were consented for tissue acquisition per IRB-approved protocol. Tumor biopsies were performed pre-treatment (day 0), at 10-14 days on treatment, and/or at time of progression if applicable. Formalin-fixed tissue was analyzed to confirm that viable tumor was present via hematoxylin and eosin (H&E) staining.
Additional tissue was snap frozen and stored in liquid nitrogen or were immediately processed for purification of RNA.
Purification of Total RNA
Samples were homogenized and disrupted using a mortar and pestle followed by use of a QIAshredder. A QIAcube was used to harvest RNA using the RNeasy Mini Protocol (Qiagen).
Quantitative PCR
Research. 
Immunohistochemistry
Tumor biopsies were stained with primary antibodies for MART-1 (Covance, SIG-38160-1000), HMB-45(gp100) (Leica, PA0027), CD4 (Leica, NCL-CD4-1F6), CD8 (Leica. PA0183), Perforin (Santa Cruz, sc-374346), TIM3 (R&D Systems, AF2365), PDL1 (LS-Bio, LS-B3368) or Granzyme B (Abcam, ab4059) followed by a secondary antibody for horseradish peroxidase and then DAB or blue chromagen. Stained slides were interpreted by a dedicated dermatopathologist. 
Counting of CD8+ T cells
Immunofluorescence
Sections from formalin-fixed paraffin-embedded (FFPE) melanoma tumor biopsies were de-paraffinized, rehydrated, and endogenous peroxidase activity was blocked in 3% hydrogen peroxide in water. After rinsing, heat-induced antigen retrieval was performed.
Non-specific binding was blocked by 20% serum blocker and endogenous avidin + biotin blocking system. Primary antibody (monoclonal antibody targeting MART-1) and FITCconjugated secondary antibody were then applied. Images were acquired using a Nikon Eclipse-80i fluorescence microscope.
Statistics
Statistics were performed using GraphPad Prism or the R-statistical package . 
Results
BRAF inhibition is associated with increased melanoma antigen expression in tumors of patients with metastatic melanoma
Given prior preclinical findings that BRAF inhibition leads to increased expression of melanoma antigens in melanoma cell lines and fresh tumor digests in vitro, we sought to validate these findings in patients with metastatic melanoma undergoing treatment with a BRAF inhibitor (patients 1-5) or combined BRAF + MEK inhibitor (Patients 6-18) (Supplementary Table S1 ). We observed a significant increase in mRNA levels for melanoma antigens assayed after treatment with BRAF inhibitor ( Figure 1A 
BRAF inhibition is associated with increased CD8+ T cell infiltrate in tumors of patients with metastatic melanoma
Next, we performed studies to test the ability of BRAF inhibition to augment T cell infiltrate based on our preclinical data showing that increased MDA expression is associated with increased recognition by antigen-specific T cells. Tumor biopsies from patients with metastatic melanoma undergoing treatment with a BRAF inhibitor were stained by H&E and using immunohistochemistry for CD8 positive cells. We observed a (Figure 2A-C) . There was no difference in CD4+ T cell infiltrate (data not shown).
BRAF inhibition is associated with decreased immunosuppressive cytokines & markers of T cell cytotoxicity but increased T cell exhaustion markers and PDL1 in tumors of patients with metastatic melanoma
Next, we analyzed the tumors of treated patients for expression of immunosuppressive cytokines, markers of T cell cytotoxicity, T cell exhaustion markers and the immunosuppressive ligand PDL1 to determine the effects of BRAF inhibition on the tumor microenvironment. BRAF inhibition was associated with a significant decrease in the expression of immunosuppressive cytokines IL-6 and IL-8, while there was no significant change in TGF-beta and IL-10 ( Figure 3A) . A significant increase in expression was also observed in markers of T cell cytotoxicity (perforin, granzyme B) ( Figure 3B ). Of note, T cell exhaustion markers TIM3 and PD1 were also significantly increased after BRAF inhibition ( Figure 3B) . Expression of the immunosuppressive ligand PDL1 was also significantly increased following treatment with a BRAF inhibitor ( Figure 3C ). These were validated using immunohistochemistry for markers with available antibodies (Figure 3D and 3E) . Of note, there was no change in HLA expression (Supplementary Figure S2) .
Melanoma antigen expression and CD8+ T cell infiltrate are decreased at time of progression and restored through MEK inhibition
Tumor biopsies from patients with metastatic melanoma undergoing treatment with a BRAF inhibitor who progressed on therapy were assayed for melanoma antigen expression and CD8+ T cell infiltrate as described previously. At the time of 
progression, there was a significant decrease in melanoma antigen expression ( Figure 4A and Supplementary Figure S3 ) and CD8+ T cell infiltrate. One of these patients was later enrolled on a combination trial incorporating combined BRAF + MEK inhibition (dabrafenib + trametinib) after progressing on BRAF monotherapy. A tumor biopsy performed after inititation of combined BRAF + MEK therapy showed restoration of melanoma antigen expression and CD8+ T cell infiltrate (Figure 4A-C) .
Discussion
The advent of therapy with BRAF inhibitors has produced remarkable clinical success (6) and brought new hope for patients with metastatic melanoma. However, the impressive response rates have been tempered by a short duration of response in the majority of patients (6) . There is an intense effort underway to better understand mechanisms of resistance to BRAF-targeted therapy (7-9, 13), with several strategies proposed to counter this resistance. Combination with other targeted agents (14) More recently, our group and others have provided supporting evidence for these in vitro findings, demonstrating an increase in tumor infiltrating lymphocytes in patients with metastatic melanoma treated with BRAF inhibitors (15, 16 ). An increase in immune infiltrate was seen in virtually all patients though the response to treatment was variable, raising the question as to whether the increase in T cell infiltrate is directly related to MAPK pathway blockade or if it is secondary to tumor necrosis. The results in Figure 4 showing restored T cell infiltrate with combination BRAF + MEK would suggest that the increased T cell infiltrate is more likely due to MAPK pathway inhibition, though further studies are necessary to better understand the response. 
